Doxazosin and DZ-50 were both found to exert potent antitumor action against human renal cancer cell lines 786-0 (harboring a VHL tumor-suppressor gene mutation and a highly angiogenic phenotype) and Caki cells (without a VHL mutation) [3]. This evidence concerns the gene VHL and renal carcinoma.